Bris­tol My­er­s' im­munother­a­py com­bo nets ap­provals in col­orec­tal and liv­er can­cer

Bris­tol My­ers Squibb’s com­bined im­munother­a­pies Op­di­vo and Yer­voy won ap­proval this week as a first-line treat­ment for metasta­t­ic liv­er can­cer and cer­tain forms of col­orec­tal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER